(Reuters) -The U.S. Food and Drug Administration is probing the death of a patient who developed harmful antibodies after taking Takeda Pharmaceuticals' blood disorder therapy, the health regulator said on Friday.
The pediatric patient died about 10 months after starting Takeda's drug Adzynma as a preventive therapy, the agency said.
The child had congenital thrombotic thrombocytopenic purpura (cTTP), an inherited condition that causes blood clots in small vessels and can lead to organ damage.
The FDA said the child developed antibodies that blocked the activity of ADAMTS13, an enzyme critical for blood clotting.
Takeda did not immediately respond to Reuters request for comment.
Adzynma, approved in 2023 as the first therapy for cTTP, replaces the ADAMTS13 protein to help prevent dangerous blood clots.
The agency added it has received multiple postmarketing reports of patients developing neutralizing antibodies to ADAMTS13 after treatment with Adzynma.
(Reporting by Kamal Choudhury in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
Could it be said that you are As yet Utilizing Old Tires? at These 6 Tire Brands - 2Careful Nurturing: Techniques for Bringing up Tough Children
- 3Kaiser Permanente affiliates to pay $556 million to resolve US claims alleging Medicare fraud
- 4Novo Nordisk cuts Wegovy price as CEO pledges to go 'all in' on weight loss pill
- 5RFK Jr.’s vaccine advisers plan biggest change yet to childhood schedule
- Israel says 40 Hezbollah members killed as forces advance in Lebanon
- Becoming amazing at Arranging Pay Raises
- Kelsey Grammer on having a new baby at 70: 'You're just more available now'
- U.K. blocks Kanye West from entering Britain to headline now canceled festival: What led to the ban
- 7 Odd Apparatuses to Make Your Party Stick Out!
- Warship sunk by British fleet, remains of sailor found after 225 years
- Party Urban areas of the World
- Vote In favor of Your Favored Menial helper Administration
- Moon rocket and weather are on NASA's side for the first astronaut launch in decades
